CY1105159T1 - (ιμιδαζολ-1-υλο-μεθυλο)-πυριδαζινη ως παρεμποδιστης υποδοχεα νμda - Google Patents
(ιμιδαζολ-1-υλο-μεθυλο)-πυριδαζινη ως παρεμποδιστης υποδοχεα νμdaInfo
- Publication number
- CY1105159T1 CY1105159T1 CY20061101161T CY061101161T CY1105159T1 CY 1105159 T1 CY1105159 T1 CY 1105159T1 CY 20061101161 T CY20061101161 T CY 20061101161T CY 061101161 T CY061101161 T CY 061101161T CY 1105159 T1 CY1105159 T1 CY 1105159T1
- Authority
- CY
- Cyprus
- Prior art keywords
- disease
- neurodegeneration
- compounds
- nmda receptor
- formula
- Prior art date
Links
- GFSWLEBKUPUQNQ-UHFFFAOYSA-N 3-(imidazol-1-ylmethyl)pyridazine Chemical compound C1=CN=CN1CC1=CC=CN=N1 GFSWLEBKUPUQNQ-UHFFFAOYSA-N 0.000 title 1
- 239000003703 n methyl dextro aspartic acid receptor blocking agent Substances 0.000 title 1
- 150000001875 compounds Chemical class 0.000 abstract 3
- 230000004770 neurodegeneration Effects 0.000 abstract 3
- 208000002193 Pain Diseases 0.000 abstract 2
- 206010002026 amyotrophic lateral sclerosis Diseases 0.000 abstract 2
- 230000001684 chronic effect Effects 0.000 abstract 2
- 208000024827 Alzheimer disease Diseases 0.000 abstract 1
- 208000035143 Bacterial infection Diseases 0.000 abstract 1
- 208000000094 Chronic Pain Diseases 0.000 abstract 1
- 208000023105 Huntington disease Diseases 0.000 abstract 1
- 102000004868 N-Methyl-D-Aspartate Receptors Human genes 0.000 abstract 1
- 108090001041 N-Methyl-D-Aspartate Receptors Proteins 0.000 abstract 1
- 208000018737 Parkinson disease Diseases 0.000 abstract 1
- 208000030886 Traumatic Brain injury Diseases 0.000 abstract 1
- 208000036142 Viral infection Diseases 0.000 abstract 1
- 239000002253 acid Substances 0.000 abstract 1
- 230000001154 acute effect Effects 0.000 abstract 1
- 208000005298 acute pain Diseases 0.000 abstract 1
- 125000000217 alkyl group Chemical group 0.000 abstract 1
- 230000001580 bacterial effect Effects 0.000 abstract 1
- 208000022362 bacterial infectious disease Diseases 0.000 abstract 1
- 125000004122 cyclic group Chemical group 0.000 abstract 1
- 229910052739 hydrogen Inorganic materials 0.000 abstract 1
- 239000001257 hydrogen Substances 0.000 abstract 1
- 125000004435 hydrogen atom Chemical group [H]* 0.000 abstract 1
- 150000003839 salts Chemical class 0.000 abstract 1
- 230000001225 therapeutic effect Effects 0.000 abstract 1
- 230000009385 viral infection Effects 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
- C07D409/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing three or more hetero rings
Landscapes
- Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Pharmacology & Pharmacy (AREA)
- General Chemical & Material Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Neurosurgery (AREA)
- Neurology (AREA)
- Biomedical Technology (AREA)
- Engineering & Computer Science (AREA)
- Psychiatry (AREA)
- Oncology (AREA)
- Communicable Diseases (AREA)
- Pain & Pain Management (AREA)
- Virology (AREA)
- Hospice & Palliative Care (AREA)
- Addiction (AREA)
- Psychology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
Abstract
Η παρούσα εφεύρεση σχετίζεται με ενώσεις του τύπου (I) όπου το Α είναι μια μη υποκατεστημένη κυκλική ομάδα και το R είναι υδρογόνο ή κατώτερη αλκυλομάδα και με φαρμακευτικώς αποδεκτά άλατα προσθήκης οξέος αυτών. Εχει δειχθεί ότι οι ενώσεις του τύπου ΙΑ και IB είναι καλοί ειδικοί παρεμποδιστές υποδοχέα NMDA υποτύπου NR-2B. Στις πιθανές θεραπευτικές ενδείξεις για τις ενώσεις αυτές περιλαμβάνονται οι οξείες μορφές νευροεκφυλισμού προκαλούμενου, π.χ., από εγκεφαλικό επεισόδιο και εγκεφαλικό τραύμα, και χρόνιες μορφές νευροεκφυλισμού όπως η νόσος Alzheimer, η νόσος Parkinson, η νόσος Huntington, η ALS (πλάγια μυατροφική σκλήρυνση) και ο νευροεκφυλισμός ο οποίος σχετίζεται με βακτηριακές ή ιικές λοιμώξεις και επίσης, η κατάθλιψη και ο χρόνιος ή οξύς πόνος.
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
EP02010217 | 2002-05-16 | ||
EP03752750A EP1506190B1 (en) | 2002-05-16 | 2003-05-16 | (imidazol-1-yl-methyl)-pyridazine as nmda receptor blocker |
PCT/EP2003/005151 WO2003097637A1 (en) | 2002-05-16 | 2003-05-16 | (imidazol-1-yl-methyl)-pyridazine as nmda receptor blocker |
Publications (1)
Publication Number | Publication Date |
---|---|
CY1105159T1 true CY1105159T1 (el) | 2009-11-04 |
Family
ID=29433072
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CY20061101161T CY1105159T1 (el) | 2002-05-16 | 2006-08-22 | (ιμιδαζολ-1-υλο-μεθυλο)-πυριδαζινη ως παρεμποδιστης υποδοχεα νμda |
Country Status (31)
Country | Link |
---|---|
US (1) | US7005432B2 (el) |
EP (1) | EP1506190B1 (el) |
JP (1) | JP4267569B2 (el) |
KR (1) | KR100632868B1 (el) |
CN (1) | CN1312151C (el) |
AR (1) | AR040010A1 (el) |
AT (1) | ATE329912T1 (el) |
AU (1) | AU2003242542B2 (el) |
BR (1) | BR0311177A (el) |
CA (1) | CA2485926C (el) |
CL (1) | CL2004001251A1 (el) |
CY (1) | CY1105159T1 (el) |
DE (1) | DE60306152T2 (el) |
DK (1) | DK1506190T3 (el) |
ES (1) | ES2265581T3 (el) |
HK (1) | HK1080845A1 (el) |
HR (1) | HRP20041060B1 (el) |
IL (1) | IL164922A (el) |
MA (1) | MA27117A1 (el) |
ME (1) | MEP76708A (el) |
MX (1) | MXPA04011253A (el) |
NO (1) | NO329605B1 (el) |
NZ (1) | NZ536310A (el) |
PL (1) | PL211340B1 (el) |
PT (1) | PT1506190E (el) |
RS (1) | RS51200B (el) |
RU (1) | RU2317294C2 (el) |
SI (1) | SI1506190T1 (el) |
TN (1) | TNSN04224A1 (el) |
WO (1) | WO2003097637A1 (el) |
ZA (1) | ZA200408789B (el) |
Families Citing this family (28)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US7005432B2 (en) * | 2002-05-16 | 2006-02-28 | Hoffman-La Roche Inc. | Substituted imidazol-pyridazine derivatives |
GB0218876D0 (en) * | 2002-08-13 | 2002-09-25 | Merck Sharp & Dohme | Therapeutic agents |
CN100579579C (zh) * | 2002-10-01 | 2010-01-13 | 诺华疫苗和诊断公司 | 抗癌及抗感染性疾病组合物及其使用方法 |
KR101289923B1 (ko) * | 2005-05-03 | 2013-07-25 | 메르크 파텐트 게엠베하 | 유기 전계발광 장치 및 그에 사용되는 붕산 및 보린산유도체 |
US20090054392A1 (en) * | 2007-08-20 | 2009-02-26 | Wyeth | Naphthylpyrimidine, naphthylpyrazine and naphthylpyridazine analogs and their use as agonists of the wnt-beta-catenin cellular messaging system |
JP5315710B2 (ja) * | 2008-02-07 | 2013-10-16 | セントラル硝子株式会社 | 1−ブロモ−3−フルオロ−5−ジフルオロメチルベンゼンの製造方法 |
DE102008015033A1 (de) | 2008-03-17 | 2009-09-24 | Aicuris Gmbh & Co. Kg | Substituierte (Pyrazolyl-carbonyl)imidazolidinone und ihre Verwendung |
EP2254580A1 (en) * | 2008-03-27 | 2010-12-01 | EVOTEC Neurosciences GmbH | Methods for treating disorders using nmda nr2b-subtype selective antagonist |
GEP20146004B (en) | 2009-02-05 | 2014-01-10 | Takeda Pharmaceuticals Co | Pyridazinone compounds |
JP5785548B2 (ja) | 2010-08-04 | 2015-09-30 | 武田薬品工業株式会社 | 縮合複素環化合物 |
WO2012019106A2 (en) * | 2010-08-06 | 2012-02-09 | Board Of Regents Of The University Of Nebraska | Positive and negative modulators of nmda receptors |
WO2013160728A1 (en) | 2012-04-26 | 2013-10-31 | Alma Mater Studiorum - Universita' Di Bologna | Dual targeting compounds for the treatment of alzheimer's disease |
US9981950B2 (en) * | 2014-08-15 | 2018-05-29 | Janssen Pharmaceuticals, Inc. | Triazoles as NR2B receptor inhibitors |
SG11201806750WA (en) | 2016-02-10 | 2018-09-27 | Janssen Pharmaceutica Nv | Substituted 1,2,3-triazoles as nr2b-selective nmda modulators |
EP3416959B1 (en) | 2016-02-18 | 2021-05-12 | Syngenta Participations AG | Pesticidally active pyrazole derivatives |
WO2017158151A1 (en) | 2016-03-18 | 2017-09-21 | Savira Pharmaceuticals Gmbh | Pyrimidone derivatives and their use in the treatment, amelioration or prevention of a viral disease |
WO2017158147A1 (en) | 2016-03-18 | 2017-09-21 | Savira Pharmaceuticals Gmbh | Pyrimidone derivatives and their use in the treatment, amelioration or prevention of a viral disease |
TW201819376A (zh) | 2016-10-06 | 2018-06-01 | 比利時商健生藥品公司 | 經取代之1H-咪唑並[4,5-b]吡啶-2(3H)-酮及其作為GLUN2B受體調節劑之用途 |
WO2018119374A1 (en) | 2016-12-22 | 2018-06-28 | Cadent Therapeutics | Nmda receptor modulators and uses thereof |
US11008302B2 (en) | 2018-04-04 | 2021-05-18 | Janssen Pharmaceutica Nv | Substituted pyridine and pyrimidines and their use as GluN2B receptor modulators |
FI3830092T3 (fi) | 2018-08-03 | 2023-07-21 | Novartis Ag | Heteroaromaattiset NMDA-reseptorimodulaattorit ja niiden käytöt |
EP3983074A1 (en) | 2019-06-14 | 2022-04-20 | Janssen Pharmaceutica NV | Pyridine carbamates and their use as glun2b receptor modulators |
EP3983072A1 (en) | 2019-06-14 | 2022-04-20 | Janssen Pharmaceutica NV | Pyrazine carbamates and their use as glun2b receptor modulators |
AU2020292994A1 (en) | 2019-06-14 | 2022-01-06 | Janssen Pharmaceutica Nv | Substituted pyrazolo-pyrazines and their use as GluN2B receptor modulators |
US11161846B2 (en) | 2019-06-14 | 2021-11-02 | Janssen Pharmaceutica Nv | Substituted pyrazolo[4,3-b]pyridines and their use as GluN2B receptor modulators |
EP3983075A1 (en) | 2019-06-14 | 2022-04-20 | Janssen Pharmaceutica NV | Substituted pyrazolo-pyridine amides and their use as glun2b receptor modulators |
CA3143276A1 (en) | 2019-06-14 | 2020-12-17 | Janssen Pharmaceutica Nv | Substituted heteroaromatic pyrazolo-pyridines and their use as glun2b receptor modulators |
CN114478210A (zh) * | 2022-02-26 | 2022-05-13 | 江苏壹药新材料有限公司 | 一种7-氯萘-2-甲醛的合成方法 |
Family Cites Families (12)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
AU717140B2 (en) | 1996-03-08 | 2000-03-16 | F. Hoffmann-La Roche Ag | Use of 4-phenyl-3,6-dihydro-2H-pyridyl derivatives as NMDA receptor subtype blockers |
CA2220649C (en) | 1996-12-03 | 2007-02-13 | F. Hoffmann-La Roche Ag | 4-hydroxy-piperidine derivatives |
US6015824A (en) * | 1998-02-10 | 2000-01-18 | Hoffmann-La Roche Ag | Pyrrolidine and piperidine derivatives and treatment of neurodegenerative disorders |
TWI254043B (en) | 1999-06-08 | 2006-05-01 | Hoffmann La Roche | Ethanesulfonyl-piperidine derivatives having good affinity to N-methyl-D-aspartate (NMDA) receptor |
ATE257827T1 (de) | 1999-07-21 | 2004-01-15 | Hoffmann La Roche | Triazolderivate |
US6339093B1 (en) | 1999-10-08 | 2002-01-15 | Hoffmann-La Roche Inc. | Isoquinoline derivatives |
CA2404464C (en) | 2000-04-20 | 2008-03-11 | F. Hoffmann-La Roche Ag | Pyrrolidine and piperidine derivatives and their use for the treatment of neurodegenerative disorders |
US6432985B2 (en) | 2000-04-25 | 2002-08-13 | Hoffmann-La Roche Inc. | Neuroprotective substituted piperidine compounds with activity as NMDA NR2B subtype selective antagonists |
AU2001296994A1 (en) | 2000-10-06 | 2002-04-15 | Regents Of The University Of California | Nmda receptor channel blocker with neuroprotective activity |
CA2381630A1 (en) | 2001-04-23 | 2002-10-23 | Leonard Theodore Meltzer | Method for preventing dyskinesias |
DE10120159A1 (de) | 2001-04-25 | 2002-10-31 | Merck Patent Gmbh | NMDA-Antagonisten und NMDA-Agonisten zur Behandlung von Suchterkrankungen |
US7005432B2 (en) * | 2002-05-16 | 2006-02-28 | Hoffman-La Roche Inc. | Substituted imidazol-pyridazine derivatives |
-
2003
- 2003-05-09 US US10/434,955 patent/US7005432B2/en not_active Expired - Fee Related
- 2003-05-15 AR ARP030101685A patent/AR040010A1/es active IP Right Grant
- 2003-05-16 DK DK03752750T patent/DK1506190T3/da active
- 2003-05-16 PT PT03752750T patent/PT1506190E/pt unknown
- 2003-05-16 KR KR1020047018485A patent/KR100632868B1/ko not_active IP Right Cessation
- 2003-05-16 CA CA002485926A patent/CA2485926C/en not_active Expired - Fee Related
- 2003-05-16 MX MXPA04011253A patent/MXPA04011253A/es active IP Right Grant
- 2003-05-16 JP JP2004505370A patent/JP4267569B2/ja not_active Expired - Fee Related
- 2003-05-16 ES ES03752750T patent/ES2265581T3/es not_active Expired - Lifetime
- 2003-05-16 AT AT03752750T patent/ATE329912T1/de active
- 2003-05-16 NZ NZ536310A patent/NZ536310A/en not_active IP Right Cessation
- 2003-05-16 RU RU2004136979/04A patent/RU2317294C2/ru not_active IP Right Cessation
- 2003-05-16 BR BR0311177-6A patent/BR0311177A/pt not_active IP Right Cessation
- 2003-05-16 DE DE60306152T patent/DE60306152T2/de not_active Expired - Lifetime
- 2003-05-16 AU AU2003242542A patent/AU2003242542B2/en not_active Ceased
- 2003-05-16 ME MEP-767/08A patent/MEP76708A/xx unknown
- 2003-05-16 PL PL374224A patent/PL211340B1/pl unknown
- 2003-05-16 WO PCT/EP2003/005151 patent/WO2003097637A1/en active IP Right Grant
- 2003-05-16 CN CNB038111926A patent/CN1312151C/zh not_active Expired - Fee Related
- 2003-05-16 SI SI200330332T patent/SI1506190T1/sl unknown
- 2003-05-16 EP EP03752750A patent/EP1506190B1/en not_active Expired - Lifetime
- 2003-05-16 RS YUP-985/04A patent/RS51200B/sr unknown
-
2004
- 2004-05-24 CL CL200401251A patent/CL2004001251A1/es unknown
- 2004-10-28 IL IL164922A patent/IL164922A/en not_active IP Right Cessation
- 2004-10-28 NO NO20044666A patent/NO329605B1/no not_active IP Right Cessation
- 2004-10-29 ZA ZA2004/08789A patent/ZA200408789B/en unknown
- 2004-11-11 TN TNP2004000224A patent/TNSN04224A1/fr unknown
- 2004-11-12 HR HR20041060 patent/HRP20041060B1/xx not_active IP Right Cessation
- 2004-11-12 MA MA27943A patent/MA27117A1/fr unknown
-
2006
- 2006-01-18 HK HK06100801A patent/HK1080845A1/xx not_active IP Right Cessation
- 2006-08-22 CY CY20061101161T patent/CY1105159T1/el unknown
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CY1105159T1 (el) | (ιμιδαζολ-1-υλο-μεθυλο)-πυριδαζινη ως παρεμποδιστης υποδοχεα νμda | |
MA31593B1 (fr) | Derives de 2-aza-bicyclo[3.3.0]octane | |
CY1118862T1 (el) | Νεα δικυκλικη ετεροκυκλικη ενωση | |
DE60336850D1 (en) | Substituierte arylcyclopropylacetamide als glucokinaseaktivatoren | |
CY1105631T1 (el) | Υποκατεστημενα παραγωγα καρβοστυριλης ως αγωνιστες 5-ητ1α υποτυπου δεκτη | |
MA31000B1 (fr) | Derives 2-aza-bicyclo[3.1.0]hexane | |
UY30426A1 (es) | Derivados sustituidos del 3-(4-metoxi-fenil)-3h-isoindol-1-ilamina trifluoroacetado, sus sales o solvatos farmaceuticamente aceptables, formulaciones farmacéuticas y aplicaciones. | |
MX2009010024A (es) | Nuevo compuesto de adenina. | |
EA200200248A1 (ru) | Производные 3(5)-аминопиразола, способ их получения и их применение в качестве противоопухолевых средств | |
ECSP066760A (es) | Derivado de 4-oxopirimidina de anillos condensados | |
MA32558B1 (fr) | Composes organiques | |
TW200718692A (en) | Dihydrobenzofuran derivatives and uses thereof | |
WO2009146024A8 (en) | Etomidate analogues with improved pharmacokinetic and pharmacodynamic properties | |
DE602008005238D1 (de) | Bisphenol Monoester | |
NZ596653A (en) | Total synthesis of salinosporamide a and analogs thereof | |
BRPI0606639A2 (pt) | novo processo para a preparação de indóis substituìdos | |
MY152557A (en) | 3-aminocyclopentanecarboxamides as chemokine receptor modulators | |
EP2000473A4 (en) | TREHALOSE COMPOUND AND PHARMACEUTICAL PRODUCT COMPRISING THE SAME | |
EA200800149A1 (ru) | 4,5-диарилпиррольные производные, способ их получения и применение в терапии | |
BR0316702A (pt) | xprocesso para preparação de (s)-pantoprazol | |
PT1204658E (pt) | Agonistas benzofurilpiperazina de serotonina | |
EA200970497A1 (ru) | Производные пиррола, их получение и их применение в терапии | |
TR200103532T2 (tr) | Etansulfonil-piperadin türevleri | |
BR0113348A (pt) | Pró-drogas para ligantes de receptores de nmda | |
TW200801016A (en) | Thienopyridine-2-carboxamide derivatives |